Global Basal cell Carcinoma Therapeutics Market 2018-2022

Want to get a preview about what to expect from Technavio’s market research report? Check out the latest facts about the basal cell carcinoma therapeutics industry

The global basal cell carcinoma therapeutics market is forecasted to grow at a CAGR of almost 6% during the period of the forecast

Basal cell carcinoma therapeutics industry growth is expected to accelerate over the next five years, driven by heavy investments to develop a strong R&D department for basal cell carcinoma treatment. Cancer is considered one of the most common causes of death across the globe, and the prevalence of cancer has witnessed a rapid surge in the past few years. According to a research article published by the American Society of Clinical Oncology (ASCO), around 14 million people are predicted to develop cancer in 2018, and almost nine people die of cancer every year. The growing rate of incidence of cancer has resulted in a growing need to develop more effective basal cell carcinoma treatment, which is expected to contribute to the growth of the global basal cell carcinoma therapeutics market. Technavio’s basal cell carcinoma therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Americas will drive the largest incremental growth for the global basal cell carcinoma therapeutics market

About 44% of the incremental growth in the global basal cell carcinoma therapeutics market will be driven by the Americas, followed by EMEA and APAC making reasonable contributions to the market growth during the period of forecast. Furthermore, the Americas held the dominant share of more than half of the global basal cell carcinoma therapeutics market towards the end of 2017. Factors such as the rising prevalence of basal cell carcinoma, a well-defined healthcare infrastructure, and the growing number of initiatives taken by the US government are expected to drive the growth of the market in the region. However, APAC is expected to display the fastest rate of growth during the forecasted period, while EMEA will register a higher CAGR than the Americas over the next five years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

Bausch Health, Biofrontera, and F. Hoffmann-La Roche are among the leading basal cell carcinoma therapeutic companies

The global basal cell carcinoma therapeutics market was marginally concentrated at the end of 2017, with the presence of a few international and regional basal cell carcinoma therapeutic companies who offer all the currently approved therapeutics for the treatment of basal cell carcinoma. Some of the established pharmaceutical companies and various government organizations are investing heavily in the R&D of novel therapies, which is currently dominated by biologic molecules due to their high efficacy. Many international and regional basal cell carcinoma therapeutic companies are vying for their share of the global basal cell carcinoma therapeutics market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several basal cell carcinoma therapeutic companies, including:

• Bausch Health
• Biofrontera
• F. Hoffmann-La Roche
• Mylan
• Sun Pharmaceutical

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch